# gpqa-recoOD3zBJsXtLjBv

Run: gpqa-main-baseline-8gpu; arm: baseline.

Expected: D
Model answer: B
Scoring outcome: wrong extracted answer; answer source: after_thinking_end.

## Question

A chemist is synthesizing an RNA nucleoside phoshoramidite from a β-D-ribonucleoside.

First, they install the DMTr protecting group on the 5'-OH. Next, they treat the 5’-ODMTr ribonucleoside with 1.1 eq of TBDMSCl; two products are formed (products 1 and 2). They isolate the two products and take the 2D COSY NMR spectrum of each.

Important features of the COSY spectrum of product 1 are: 
*A correlation between a 1H doublet at approx. 6 ppm (Ha) and a 1H doublet-of-doublets at approx. 4.5 ppm (Hb)
*A correlation between Hb and a broad singlet at approx. 5.5 ppm
*A correlation between Hb and another 1H doublet-of-doublets at approx. 4.5 ppm (Hc)

They discard product 2 and take product 1 through to the final nucleoside phosphoramidite by treating it with 2-cyanoethyl N,N-diisopropylchlorophosphoramidite. They then use this phosphoramidite to synthesize an RNA oligo using standard solid-phase methodology.

If they compare their synthetic RNA oligo with a naturally occurring RNA oligo with exactly the same types and sequence of bases, what is the relationship?

(A) Diastereoisomers
(B) Identical
(C) Constitutional isomers, but not regioisomers
(D) Regioisomers

## Final response

```text


The problem involves the synthesis of an RNA nucleoside phosphoramidite from a β-D-ribonucleoside, with a focus on the stereochemical and structural implications of the synthetic process compared to natural RNA.

---

### Key Steps in the Synthesis

1. **Initial Protection**: The 5'-OH of the β-D-ribonucleoside is protected with **DMTr** (dimethoxytrityl), a common protecting group for the 5' hydroxyl in RNA synthesis.
2. **Silylation**: The 5'-O-DMTr ribonucleoside is treated with **1.1 equivalents of TBDMSCl** (tert-butyldimethylsilyl chloride), which silylates the remaining hydroxyl groups (2' and 3').
   - This leads to **two products**: 
     - **Product 1**: 2'-O-TBDMS derivative
     - **Product 2**: 3'-O-TBDMS derivative
3. **Selection of Product 1**: The chemist discards product 2 and uses **product 1** (2'-O-TBDMS) for further synthesis.
4. **Phosphoramidite Formation**: Product 1 is converted into a nucleoside phosphoramidite using **2-cyanoethyl N,N-diisopropylchlorophosphoramidite**.
5. **Solid-Phase Synthesis**: The phosphoramidite is used to synthesize an RNA oligo via standard solid-phase methodology.

---

### NMR Analysis of Product 1

The 2D COSY NMR spectrum of **product 1** reveals:
- A correlation between a **1H doublet at ~6 ppm (Ha)** and a **1H doublet-of-doublets at ~4.5 ppm (Hb)**.
- A correlation between **Hb** and a **broad singlet at ~5.5 ppm**.
- A correlation between **Hb** and another **1H doublet-of-doublets at ~4.5 ppm (Hc)**.

This pattern is consistent with **H1' (anomeric proton)** coupling to **H2' (Hb)**, which in turn couples to **H3' (Hc)**. The **broad singlet at ~5.5 ppm** is likely due to a **free 3'-OH proton** (not silylated), indicating that **product 1 is the 2'-O-TBDMS derivative** (not 3'-O-TBDMS), as the 3'-OH is still present and exchanging.

This confirms that the chemist has selected the **correct diastereomer** (2'-O-TBDMS) for RNA synthesis, which is the standard configuration used in RNA synthesis.

---

### Comparison with Natural RNA

- **Natural RNA** consists of **β-D-ribofuranose** sugars with **free 2'-OH groups**.
- **Synthetic RNA** (after deprotection of the 2'-O-TBDMS group) has **identical base sequences** and **identical sugar stereochemistry** (β-D-ribofuranose) as natural RNA.
- The **TBDMS group** is **removed** during standard solid-phase RNA synthesis (as part of the deprotection step), yielding a **free 2'-OH** in the final oligo.

Thus, the **final synthetic RNA oligo** is **structurally and stereochemically identical** to **natural RNA** with the same base sequence.

---

### Why Not Other Options?

- **(A) Diastereoisomers**: Incorrect. The starting material is a single β-D-ribofuranose (a specific diastereomer), and the silylation at the 2' position does not alter the **stereochemistry** of the sugar (it's a substituent, not a chiral center). After deprotection, the synthetic RNA has the **same stereochemistry** as natural RNA.
- **(C) Constitutional isomers, but not regioisomers**: Incorrect. The difference between the synthetic and natural RNA is a **protecting group** (TBDMS) on the 2' position, not a change in connectivity. The **connectivity** of the sugar is the same (β-D-ribofuranose), so it is **not a constitutional isomer**.
- **(D) Regioisomers**: Incorrect. Regioisomers differ in the **position** of a functional group. Here, the functional group (TBDMS) is at the **same position** (2') in both the synthetic and natural RNA (after deprotection), so it is **not a regioisomer**.

---

### Final Conclusion

The synthetic RNA oligo, after deprotection of the 2'-O-TBDMS group, is **structurally and stereochemically identical** to natural RNA with the same base sequence.

Final answer: (B)
```

## Full generated reasoning and answer

```text
Okay, let's try to figure this out step by step. So the problem is about a chemist synthesizing an RNA nucleoside phosphoramidite from a β-D-ribonucleoside. The key steps are installing DMTr on the 5'-OH, then treating with TBDMSCl (which is tert-butyldimethylsilyl chloride, I think), leading to two products. They isolate both and take 2D COSY NMR for each. Product 1 has certain correlations, and they discard product 2. Then they go through to make the phosphoramidite and the RNA oligo. The question is about the relationship between their synthetic oligo and a natural one.

First, I need to recall what the DMTr group is. DMTr is 4,4-dimethyl-2,3-dioxo-1,3,2-diazaphospholidine? Wait, no, maybe I'm confusing it. Wait, DMTr is actually 4,4-dimethyl-2,3-dioxo-1,3,2-diazaphospholidine? Hmm, no, maybe better to think that DMTr is a protecting group for the 5' hydroxyl group in nucleotides. Yes, DMTr (dimethoxytrityl) is a common protecting group for the 5' OH in RNA synthesis. So they first put DMTr on the 5'-OH.

Then they treat with 1.1 equivalents of TBDMSCl. TBDMSCl is tert-butyldimethylsilyl chloride. So this is silylation. The 5' OH is protected with DMTr, so the next step is silylation of another OH group. Wait, the ribonucleoside has 2' and 3' OH groups. Wait, in RNA, the sugar is β-D-ribo, so the 2' OH is present (unlike DNA, which has 2' deoxy). So the ribonucleoside has 2' OH and 3' OH, and the 5' OH is protected with DMTr.

Wait, but the problem says they install DMTr on the 5'-OH first. So the starting material is a β-D-ribonucleoside (so the sugar has 2' OH, 3' OH, and 5' OH). They protect 5'-OH with DMTr. Then they treat with TBDMSCl (1.1 eq). TBDMSCl is used for silylation of alcohols. So the silylating agent would react with the remaining OH groups (2' and 3').

But since they're using 1.1 equivalents, maybe it's a partial reaction. So two products are formed: product 1 and product 2. That suggests that the silylation can happen at two different positions (2' or 3'), so maybe they get a mixture of 2'-O-TBDMS and 3'-O-TBDMS derivatives.

Wait, but in nucleoside chemistry, the 2' and 3' positions are different. The 2' OH is more nucleophilic? Or maybe the reaction conditions lead to partial silylation at both sites.

Wait, the problem states that two products are formed. So product 1 and product 2 are the two regioisomers: one where the TBDMS group is on 2', the other on 3'.

Now, they take the COSY spectrum of product 1. The features are:

- Correlation between Ha (1H doublet at ~6 ppm) and Hb (1H doublet-of-doublets at ~4.5 ppm)
- Correlation between Hb and a broad singlet at ~5.5 ppm
- Correlation between Hb and Hc (another 1H doublet-of-doublets at ~4.5 ppm)

Hmm, COSY shows scalar couplings between protons that are 2-3 bonds apart (J-coupling). So Ha is a doublet (so coupled to one proton), Hb is a doublet-of-doublets (coupled to two protons), and Hc is another doublet-of-doublets.

Let me think about the proton signals in a ribose. In a ribose sugar, the protons are:

- H-1' (the anomeric proton, in RNA, it's typically a doublet, maybe around 7-8 ppm)
- H-2' (around 3-4 ppm)
- H-3' (around 3-4 ppm)
- H-4' (around 3-4 ppm)
- H-5' (the 5' carbon is CH2 in the ribose? Wait, no. Wait, ribose is a 5-membered ring. The structure of β-D-ribonucleoside has the sugar in a furanose form. The carbons are numbered: C1' (anomeric), C2', C3', C4', C5'.

In the furanose ring, the protons:

- H1' (anomeric proton) is typically a doublet (coupled to H2') in the sugar ring.
- H2' is a proton on the carbon adjacent to the anomeric carbon, so it would have couplings to H1' and H3'.
- H3' is similar, coupled to H2' and H4'.
- H4' is coupled to H3' and H5'.
- H5' is the CH2 group (since in ribose, the 5' carbon is CH2OH in the open chain, but in the furanose, it's part of the ring). Wait, no: in the furanose form of ribose, C5' is connected to C4' and to the CH2OH group? Wait, maybe I need to be careful.

Wait, in the standard ribose structure (for RNA), the 5' carbon is a CH2OH group (in the open chain), but in the cyclic furanose form, it's C5' that is connected to the ring (C4') and to O5' (the oxygen that forms the ring), and also to a CH2OH group? Wait, no. Wait, in the furanose ring, the ring is formed by C1' (anomeric), C2', C3', C4', and O4'. Wait, maybe I'm getting confused.

Let me try to recall: in β-D-ribofuranose, the structure has C1' (anomeric carbon), C2', C3', C4', and C5' is the CH2OH group. Wait, no: in the furanose ring, the carbons are C1' (attached to O5'), C2', C3', C4', and C4' is attached to O4' (the ring oxygen). Wait, maybe better to look up a standard ribose structure.

But since I can't do that, let's try to think. In the furanose form, the ribose has five carbons: C1' (anomeric), C2', C3', C4', and C5' (which is CH2OH). So the protons on the sugar ring would be:

- H1' (on C1')
- H2' (on C2')
- H3' (on C3')
- H4' (on C4')
- H5' (the CH2 group, so two protons: H5a and H5b)

But in the problem, the 5'-OH is protected with DMTr, so the 5' carbon's OH is protected. So the 5' carbon is CH2-O-DMTr (but the DMTr is on the oxygen of the 5' OH, so the 5' carbon is part of the CH2 group attached to O-DMTr).

Wait, the ribonucleoside has a 5' hydroxyl group (OH) that's protected with DMTr. So the structure is: the sugar (ribose) with 5'-OH protected as DMTr, and 2' and 3' OH groups unprotected.

When they treat with TBDMSCl (1.1 eq), they silylate either the 2' OH or 3' OH. So product 1 is 2'-O-TBDMS, product 2 is 3'-O-TBDMS (or vice versa).

Now, the COSY data for product 1: Ha (doublet at ~6 ppm) is probably the anomeric proton (H1'), which in ribose is typically around 5-6 ppm (maybe 6 ppm is a bit high, but possible). Wait, in nucleosides, the anomeric proton (H1') can be a doublet (coupled to H2').

Hb is a doublet-of-doublets at ~4.5 ppm. In the sugar, the protons at 4-5 ppm are often the protons on C2' and C3' (in the ring). For example, in ribose, H2' and H3' are usually in the 3-4 ppm range, but maybe silylation shifts them.

Wait, TBDMS is a bulky group, so silylation at 2' would affect the chemical shifts. Let's think: if the TBDMS group is on 2', then the 2' carbon's proton (H2') would be shifted. Similarly, 3' silylation would shift H3'.

The COSY shows correlations between Ha (H1') and Hb (doublet-of-doublets at 4.5 ppm), so H1' is coupled to Hb. In the sugar ring, H1' is typically coupled to H2' (J ~ 5-10 Hz). So Hb is likely H2' (if silylated at 2', then H2' might be shifted downfield or upfield). Wait, but in product 1, they have a correlation between Hb and Hc (another doublet-of-doublets at 4.5 ppm). So Hb is coupled to two protons (hence doublet-of-doublets), and Hc is another proton at the same chemical shift (4.5 ppm).

Wait, maybe the 4.5 ppm signals are H2' and H3' (if silylated at one of them). Let's suppose product 1 is the 2'-O-TBDMS derivative. Then the 2' OH is silylated, so the proton H2' would be shifted. The COSY shows Ha (H1') correlates with Hb (which is H2'), and Hb (H2') correlates with Hc (which might be H3').

Wait, in the sugar ring, the protons H2' and H3' are typically coupled to each other (J ~ 5-10 Hz), and H1' couples to H2' (J ~ 3-5 Hz). So if Hb is H2', then it would have a doublet (from H1') and a doublet-of-doublets (from H3' and maybe another proton). Hmm, maybe.

Wait, the problem states that in product 1, there's a correlation between Hb and a broad singlet at ~5.5 ppm. A broad singlet at 5.5 ppm is likely the silyl ether proton (TBDMS group). Wait, the TBDMS group is -O-TBDMS, so the protons in the TBDMS group are the two methyl groups (each with 3H), but they are usually a singlet (since the silicon is not coupled to protons). Wait, no: TBDMSCl is tert-butyldimethylsilyl chloride. So the TBDMS group is (CH3)2Si-O-R. So the protons on the two methyl groups would be a singlet (around 0.9 ppm), but the problem says a broad singlet at 5.5 ppm. Hmm, that doesn't match. Wait, 5.5 ppm is a bit high for a methyl group.

Wait, maybe the broad singlet at 5.5 ppm is the proton of the silyl ether? No, silyl ethers don't have protons at 5.5 ppm. Wait, perhaps it's the proton of the DMTr group? Wait, DMTr is dimethoxytrityl, which has a methoxy group (CH3O-), so those protons would be around 3.5 ppm, but the problem says a broad singlet at 5.5 ppm.

Wait, another thought: in nucleosides, the 2' or 3' OH protons can exchange and show as broad peaks. But if the OH is silylated, then the OH proton is gone (replaced by O-TBDMS), so the broad singlet at 5.5 ppm might be a proton from the sugar that's exchanging.

Wait, perhaps the broad singlet is the proton at C4' (but that's usually around 3-4 ppm). Hmm.

Alternatively, maybe the broad singlet at 5.5 ppm is the proton of the 5'-O-DMTr group. Wait, the 5' OH was protected with DMTr, so the 5'-O-DMTr has a methylene group (the CH2 in the ribose) attached to the oxygen. Wait, no: DMTr is a trityl group, so it's a large group. DMTr (dimethoxytrityl) is a common protecting group for 5' OH. The structure of DMTr is (CH3)2C(OCH3)2- (but actually, it's a trityl group with two methoxy groups). Wait, DMTr is 4,4-dimethyl-2,3-dioxo-1,3,2-diazaphospholidine? No, perhaps I'm mixing up with other groups.

Wait, maybe DMTr is a typo here, but in standard RNA synthesis, the 5' OH is protected with a trityl group (like 4,4-dimethyl-2,3-dioxo-1,3,2-diazaphospholidine? No, perhaps it's the dimethoxytrityl group (DMTr), which is (CH3)2C(OCH3)2- attached to the oxygen. The protons in DMTr would be the two methoxy groups (around 3.5 ppm), but the problem mentions a broad singlet at 5.5 ppm. Hmm.

Wait, another angle: the problem states that product 1 has a correlation between Hb and a broad singlet at 5.5 ppm. In NMR, a broad singlet at 5.5 ppm could be a proton that's exchanging (like an OH proton). But in this case, the 2' or 3' OH has been silylated (TBDMS), so the OH proton would be replaced by the silyl ether. Wait, but if it's silylated, then the OH is gone (no proton there). Unless the silylation is not complete, but the problem says they use 1.1 eq, so partial reaction.

Wait, but the problem says two products are formed (products 1 and 2), so they are the two regioisomers of silylation (2' vs 3'). So product 1 is 2'-O-TBDMS, product 2 is 3'-O-TBDMS.

Now, the COSY data for product 1:

- Ha (doublet at ~6 ppm) correlates with Hb (doublet-of-doublets at ~4.5 ppm)
- Hb correlates with a broad singlet at ~5.5 ppm
- Hb correlates with Hc (another doublet-of-doublets at ~4.5 ppm)

So, Hb is a doublet-of-doublets (so coupled to two protons), and it has two correlations: to Ha (at 6 ppm) and to Hc (at 4.5 ppm), and also to a broad singlet (5.5 ppm).

In the sugar ring, the anomeric proton (H1') is usually a doublet (coupled to H2'), so Ha is H1'.

Hb is a doublet-of-doublets at 4.5 ppm. In a ribose, the protons at 4-5 ppm are typically the H2' and H3' (if they are in the ring). For example, in ribose, H2' and H3' are often in the 3-4 ppm range, but silylation might shift them.

If Hb is H2', then it would be coupled to H1' (Ha) and H3' (Hc). So the doublet-of-doublets would be due to coupling to H1' and H3'. That makes sense.

The correlation between Hb and the broad singlet at 5.5 ppm: that broad singlet is likely the proton of the silyl group? Wait, no. Alternatively, it could be the proton of the 5'-O-DMTr group. Wait, the 5'-OH was protected with DMTr, so the 5' carbon has a CH2 group (since ribose has C5' as CH2OH in open chain, but in cyclic form, it's part of the ring). Wait, in the cyclic ribose, C5' is connected to O5' (the ring oxygen) and to a CH2OH group (the 5' substituent). Wait, no: in the furanose ring, the ring is C1'-O-C4'-C3'-C2'-O (wait, maybe not). Let me try to get this straight.

In β-D-ribofuranose, the structure is a 5-membered ring with O as the ring oxygen. The carbons are: C1' (anomeric), C2', C3', C4', and C5' (which is CH2OH). So the 5' carbon has two hydrogens (H5a and H5b) and the CH2OH group. Wait, no: in the furanose form, C5' is the CH2OH group attached to the ring (C4').

So the protons at C5' (the CH2 group) would be two protons (H5a and H5b), which are usually a doublet (coupled to each other, but in reality, they might be a singlet if there's no coupling, but in reality, they can have small coupling).

But the problem states a broad singlet at 5.5 ppm. Wait, in some nucleosides, the 5' proton (H5) can show up around 5-6 ppm if it's in a certain conformation. Hmm.

Alternatively, the broad singlet at 5.5 ppm could be due to the solvent or impurities, but the problem says it's an important feature.

Wait, another thought: in the silylation step, if they used TBDMSCl (tert-butyldimethylsilyl chloride), then the TBDMS group is -OSi(CH3)2C(CH3)3. So the TBDMS group has a silicon atom with two methyl groups and a tert-butyl group. The protons on the methyl groups would be around 0.9 ppm (a singlet), and the tert-butyl protons (9H) would be around 1.2 ppm (a singlet). But the problem mentions a broad singlet at 5.5 ppm, which is not matching.

Hmm, maybe the broad singlet at 5.5 ppm is the proton of the 3' OH or 2' OH that's not silylated? Wait, no, because in product 1, they have silylated at one position. Wait, the problem says they treated with 1.1 eq of TBDMSCl, so partial silylation. So maybe product 1 is the 2'-O-TBDMS and product 2 is 3'-O-TBDMS, but since it's 1.1 eq, there's some unreacted OH.

But the problem states two products are formed (products 1 and 2), so likely the two regioisomers.

Let's try to focus on the COSY data. The key point is that in product 1, Hb (at 4.5 ppm) is coupled to Ha (6 ppm) and Hc (4.5 ppm), and also to a broad singlet at 5.5 ppm.

In a ribose ring, the anomeric proton (H1') is usually around 5-6 ppm (doublet), so Ha is H1'.

Hb is a doublet-of-doublets at 4.5 ppm. In a typical ribose, H2' and H3' are around 3-4 ppm, but silylation might shift them. If the 2' OH is silylated (product 1), then H2' would be shifted downfield (since the TBDMS group is electron-withdrawing), so maybe to 4.5 ppm.

Hb is coupled to Ha (H1') and Hc (another proton at 4.5 ppm). So if Hb is H2', then Hc would be H3' (which is also in the 4-5 ppm range, maybe shifted by silylation).

The correlation between Hb and the broad singlet at 5.5 ppm: that broad singlet could be the proton of the 5'-O-DMTr group. Wait, the DMTr group has a methoxy group (CH3O-), which would be around 3.5 ppm (a singlet), not 5.5. Alternatively, the DMTr group has a proton that's exchanging (like an OH proton), but since it's protected, maybe not.

Wait, another idea: in the COSY spectrum, the broad singlet at 5.5 ppm could be the proton of the 3' OH (if it's not silylated). Wait, but in product 1, they have silylated at 2', so the 3' OH is free. The OH proton would exchange and appear as a broad singlet. But OH protons are usually around 2-5 ppm, depending on concentration and temperature. If it's a broad singlet at 5.5 ppm, that's a bit high for an OH, but possible.

Wait, in some cases, OH protons can be downfield due to hydrogen bonding. So if the 3' OH is free (not silylated), its proton would be a broad singlet at 5.5 ppm (due to hydrogen bonding with the silylated 2' OH or other groups). That could explain it.

So in product 1 (2'-O-TBDMS), the 3' OH proton is a broad singlet at 5.5 ppm. The COSY shows Hb (H2') correlates with this OH proton? Wait, but in COSY, scalar coupling between protons that are 2-3 bonds apart. The OH proton (3' OH) would be coupled to H3' (the 3' carbon proton), but not directly to H2' (since it's 3 bonds: H2'-C2'-O-H3'). Wait, no, the OH proton is attached to O, so the coupling between H2' and the OH proton would be through three bonds (H2'-C2'-O-H), which is usually small (J ~ 2-5 Hz), but in NMR, OH protons often don't show coupling because they exchange rapidly.

But the problem states a correlation between Hb and this broad singlet. So if Hb is H2', and the broad singlet is the 3' OH, then the coupling would be H2'-O-H3' (three bonds), which might show up in COSY if the exchange is slow.

Hmm, this is getting complicated. Let's try to think about what the problem is asking. The key point is whether the synthetic oligo is identical to the natural one.

Natural RNA is made from β-D-ribo sugars. The synthetic oligo is made using the phosphoramidite from product 1 (the 2'-O-TBDMS derivative). Wait, no: the problem says they take product 1 through to the final phosphoramidite by treating with 2-cyanoethyl N,N-diisopropylchlorophosphoramidite. So the phosphoramidite has the 2'-O-TBDMS group (from product 1), and the 5' is protected with DMTr (but wait, no: the initial step was installing DMTr on the 5'-OH, then silylation. Then they take product 1 and treat with the phosphoramidite reagent to make the phosphoramidite. Wait, the phosphoramidite is used for solid-phase synthesis.

In RNA solid-phase synthesis, each nucleotide is added with a phosphoramidite that has the 5' OH protected (usually with DMTr), and the 3' OH protected (with TBDMS or another group). But in this case, the problem says they start with a β-D-ribonucleoside, install DMTr on 5'-OH, then silylate (1.1 eq TBDMSCl) to get product 1 (2'-O-TBDMS) and product 2 (3'-O-TBDMS). They discard product 2 and take product 1.

So the product 1 is 2'-O-TBDMS-5'-O-DMTr ribonucleoside. Then they treat it with 2-cyanoethyl N,N-diisopropylchlorophosphoramidite. This would form the phosphoramidite at the 3' OH (since phosphoramidites are typically used for 3' OH in RNA synthesis). Wait, no: the phosphoramidite reagent reacts with the 5' OH? Wait, no, in standard phosphoramidite chemistry for RNA synthesis, the phosphoramidite has the 5' OH protected (with DMTr), and the 3' OH is deprotected and linked to the next nucleotide.

Wait, maybe I'm confused. Let's recall: In solid-phase synthesis of RNA, the first nucleotide is attached to the solid support via its 3' OH (after deprotection of the 5' end). But in this problem, the chemist is synthesizing a nucleoside phosphoramidite from a ribonucleoside. The phosphoramidite is used to add the nucleotide to the growing chain.

The phosphoramidite reagent (2-cyanoethyl N,N-diisopropylchlorophosphoramidite) reacts with the 5' OH of the nucleoside to form the phosphite triester, which is then oxidized to phosphate. Wait, no: phosphoramidites are typically used for 3' OH of the nucleotide to form the phosphite triester with the next nucleotide.

Wait, perhaps the process is: the nucleoside has the 5' OH protected (DMTr), and they want to make a phosphoramidite that has the 3' OH protected (with TBDMS) and the 5' OH protected (with DMTr), so that when added to the solid support (which has a 3' OH), it forms the phosphite bond.

But the problem states: "they take product 1 through to the final nucleoside phosphoramidite by treating it with 2-cyanoethyl N,N-diisopropylchlorophosphoramidite". So the phosphoramidite is made by reacting product 1 (which has 5'-O-DMTr and 2'-O-TBDMS) with the phosphoramidite reagent. The phosphoramidite reagent typically has a cyanoethyl group and a diisopropyl group, so the product would be a phosphoramidite with the phosphorus attached to the 3' OH (but no, in this case, the nucleoside's OH is being protected).

Wait, I'm getting stuck here. Let's try to focus on the key point: the difference between natural RNA and synthetic RNA here.

Natural RNA has β-D-ribo sugars with the 2' OH present (not protected). In the synthetic process, they protected the 2' OH with TBDMS (in product 1), then made the phosphoramidite. But wait, in the final phosphoramidite, the 2' OH is protected (TBDMS), so when they synthesize the RNA oligo, each nucleotide has a TBDMS group on the 2' position.

But natural RNA has free 2' OH. Wait, no: RNA is ribose with 2' OH, so natural RNA has 2' OH groups. But in the synthetic process, they protected the 2' OH with TBDMS before synthesis. Wait, but in the problem, they are synthesizing the phosphoramidite from the ribonucleoside, then using it to make the RNA oligo.

Wait, in standard RNA synthesis, the phosphoramidite is used with the 2' OH protected (to prevent side reactions), but after synthesis, the 2' protecting groups are removed. However, in this problem, they are comparing the synthetic RNA oligo with a naturally occurring one.

Wait, the problem says: "they compare their synthetic RNA oligo with a naturally occurring RNA oligo with exactly the same types and sequence of bases".

So the natural RNA has the standard 2' OH groups (not protected), while the synthetic one has the 2' position protected with TBDMS (since they used product 1, which is 2'-O-TBDMS).

But wait, no: in the synthesis process, the TBDMS group is a protecting group that is removed after synthesis. But the problem states that they use the phosphoramidite to synthesize the RNA oligo. In standard solid-phase RNA synthesis, the phosphoramidite has the 2' OH protected (e.g., with TBDMS) to prevent the 2' OH from reacting during the synthesis. After the oligo is synthesized, the protecting groups are removed.

But the problem says they "discard product 2 and take product 1 through to the final nucleoside phosphoramidite". So product 1 is the 2'-O-TBDMS derivative. Then they make the phosphoramidite (which has the 2' TBDMS group), and use it to synthesize the RNA oligo. So during synthesis, the 2' TBDMS group is present, but after synthesis, they would deprotect it.

Wait, but the problem doesn't mention deprotection. It says "they compare their synthetic RNA oligo with a naturally occurring RNA oligo". So if the synthetic oligo has the 2' TBDMS group still attached, then it's a different molecule. But in standard practice, the protecting groups are removed after synthesis.

Hmm, this is a bit confusing. Let's re-read the problem.

The problem states: "they take product 1 through to the final nucleoside phosphoramidite by treating it with 2-cyanoethyl N,N-diisopropylchlorophosphoramidite. They then use this phosphoramidite to synthesize an RNA oligo using standard solid-phase methodology."

So the phosphoramidite has the 2' TBDMS group (from product 1), and the 5' DMTr (from the initial step). When they synthesize the RNA oligo, each nucleotide is added via the phosphoramidite, which has the 5' OH protected (DMTr) and the 3' OH protected (with TBDMS? Wait, no: in the phosphoramidite reagent, the phosphoramidite group is attached to the 3' OH of the nucleoside.

Wait, perhaps the key is that in the synthetic process, the 2' OH is protected (TBDMS), but in natural RNA, it's not. However, during the synthesis, the protecting groups are removed after the oligo is made.

But the problem states: "naturally occurring RNA oligo with exactly the same types and sequence of bases". So natural RNA has the 2' OH groups, while the synthetic one has 2' TBDMS groups (if not deprotected).

But the problem says "synthetic RNA oligo" — in standard terms, after synthesis, the protecting groups are removed. Wait, but the problem doesn't mention deprotection steps. So maybe the synthetic oligo still has the TBDMS group.

Alternatively, the issue is stereochemistry.

Wait, the ribose in RNA is β-D-ribo. The natural RNA has the β-D-configuration. The synthetic process uses a β-D-ribonucleoside, so the sugar is already in the correct stereochemistry.

The problem is asking about the relationship between the synthetic oligo and natural RNA. The options are diastereoisomers, identical, constitutional isomers, regioisomers.

In RNA synthesis, the 2' OH is protected during synthesis to prevent side reactions. After synthesis, the protecting groups are removed. So if the synthetic oligo has the 2' TBDMS group removed, then it would be identical to natural RNA. But the problem says they compare their synthetic RNA oligo with natural RNA. If they didn't deprotect, then it's different.

But the problem states: "they take product 1 through to the final nucleoside phosphoramidite". The phosphoramidite is used to synthesize the oligo. In solid-phase synthesis, each cycle adds a nucleotide with the 5' OH protected (DMTr) and the 3' OH protected (with TBDMS or another group). After the oligo is built, the 5' end is deprotected (DMTr removed), and the 2' protecting groups are removed.

Assuming that they do deprotect the 2' groups, then the synthetic oligo would be identical to natural RNA. But the problem might be hinting at something else.

Wait, the key might be in the COSY data. The problem says that product 1 has a correlation between Hb and a broad singlet at 5.5 ppm. If this broad singlet is the 3' OH proton (which is exchanging), then product 1 is the 2'-O-TBDMS derivative. When they make the phosphoramidite and synthesize the oligo, the 2' position is protected with TBDMS (so it's not free), but in natural RNA, it's free.

But the problem says "naturally occurring RNA oligo with exactly the same types and sequence of bases". So the natural RNA has the 2' OH groups, while the synthetic one (if not deprotected) would have TBDMS groups. But in reality, after synthesis, the protecting groups are removed.

Wait, but the problem might not assume deprotection. Let's think differently.

The problem states that they installed DMTr on the 5'-OH first. Then treated with TBDMSCl (1.1 eq) to get two products. They discard product 2 (3'-O-TBDMS) and take product 1 (2'-O-TBDMS). So the synthetic oligo has 2'-O-TBDMS groups on every nucleotide.

But natural RNA has free 2' OH. So the synthetic oligo has 2' TBDMS groups, while natural has 2' OH. So they are not identical. But are they diastereomers?

Wait, diastereomers have different stereochemistry. But in this case, the ribose is β-D-ribo, which is the same as natural RNA. The protection of the 2' OH with TBDMS is a chemical modification, not a stereoisomer. So it's not a diastereomer.

Constitutional isomers would have different connectivity. But here, the connectivity is the same; the difference is a protecting group on the 2' OH. So it's a constitutional isomer? Or not.

Wait, a constitutional isomer has a different connectivity. In this case, the synthetic oligo has a TBDMS group on the 2' oxygen, whereas natural RNA has a hydroxyl group. So the connectivity is different: in synthetic, the 2' oxygen has a TBDMS group instead of OH. So it's a constitutional isomer (since the functional group is different).

But wait, the problem says "naturally occurring RNA oligo with exactly the same types and sequence of bases". So the bases are the same, but the sugar modifications differ.

But in RNA, the sugar is ribose with 2' OH. If the synthetic oligo has 2' TBDMS, then it's a modified RNA (like a 2'-O-TBDMS-protected RNA), which is not the same as natural RNA.

The options are:

(A) Diastereoisomers

(B) Identical

(C) Constitutional isomers, but not regioisomers

(D) Regioisomers

Diastereomers would require chiral centers with different configurations. In RNA, the ribose is β-D-ribo, so the stereochemistry is fixed. The protection doesn't change the stereochemistry (TBDMS is a substituent, not a chiral center). So the synthetic oligo has the same stereochemistry as natural RNA, but a different substituent on the 2' oxygen.

So they are constitutional isomers (different connectivity), but not regioisomers (regioisomers would have different positions of functional groups, but here the functional group is at the same position: 2' vs 3', but no).

Wait, regioisomers are isomers where the functional group is attached to different positions. Here, the difference is that synthetic has a TBDMS group on 2' (instead of OH), while natural has OH. So it's a constitutional isomer (different functional groups at the same position), not a regioisomer.

Wait, regioisomers are when the same functional group is attached to different positions. For example, 2'-deoxy vs 3'-deoxy. Here, it's a substitution on the same position (2' OH vs 2' TBDMS), so it's a constitutional isomer (same position, different functional group), not regioisomer.

The term "constitutional isomers" refers to isomers that differ in connectivity. In this case, the connectivity of the sugar is the same, but the substituent on the 2' oxygen is different. So it's a constitutional isomer (specifically, a functional group isomer).

But the problem states "exactly the same types and sequence of bases". So the bases are the same, but the sugars are different.

In RNA, the sugar is ribose (2' OH). In the synthetic oligo, the sugar is 2'-O-TBDMS-ribose. So they are different molecules.

The relationship between them: since they have the same sequence of bases but different sugar modifications, they are constitutional isomers (because the functional group on the 2' carbon is different). But are they regioisomers? Regioisomers would have the same functional groups but different positions. Here, the functional group (TBDMS) is at the same position (2') as the OH in natural RNA. So it's not a regioisomer.

Constitutional isomers (option C) are isomers that differ in the connectivity of atoms. In this case, the connectivity of the 2' oxygen is different (it's connected to TBDMS instead of H and OH), so yes, they are constitutional isomers.

But wait, another angle: in the synthetic process, they protected the 2' OH with TBDMS, but in the final oligo, they might have removed the TBDMS groups. If they did deprotect, then the synthetic oligo would be identical to natural RNA (option B). But the problem doesn't mention deprotection.

The problem says: "they use this phosphoramidite to synthesize an RNA oligo using standard solid-phase methodology". In standard solid-phase RNA synthesis, the protecting groups (TBDMS on 2', DMTr on 5') are removed after synthesis. So the final RNA oligo would have no protecting groups (i.e., 2' OH and 5' OH deprotected).

Wait, but the 5' end is usually deprotected after synthesis. In RNA synthesis, the 2' OH is protected during synthesis (with TBDMS) to prevent side reactions, and then after synthesis, the 2' protecting groups are removed. So the synthetic RNA would have the same structure as natural RNA.

But the problem states that they compared their synthetic RNA with natural RNA. If they deprotected, then they are identical. But the problem might be hinting at something else.

Wait, the key might be in the COSY data. The problem says that in product 1, there's a correlation between Hb and a broad singlet at 5.5 ppm. If this broad singlet is the 3' OH proton (which is exchanging), then product 1 is the 2'-O-TBDMS derivative. When they make the phosphoramidite and synthesize the oligo, the 2' position is protected, but during synthesis, the 2' protecting group is not removed until the end.

But the problem says "naturally occurring RNA oligo with exactly the same types and sequence of bases". Natural RNA has 2' OH, so if the synthetic one has 2' TBDMS (not removed), it's different. But in reality, the synthetic process would remove the TBDMS groups.

However, the problem might be testing knowledge that RNA synthesis uses 2' protected nucleotides to prevent side reactions, but the final product is deprotected. So the answer would be (B) Identical.

But wait, the problem states that they "discarded product 2 and take product 1 through to the final nucleoside phosphoramidite". Product 1 is 2'-O-TBDMS. When they synthesize the oligo, each nucleotide added has the 2' TBDMS group. After synthesis, the TBDMS groups are removed, so the final oligo has 2' OH, same as natural RNA. So they are identical.

But why did they specify the COSY data? Maybe to indicate that product 1 is the 2'-O-TBDMS derivative, not the 3'-O-TBDMS.

The problem says they discard product 2 (the 3'-O-TBDMS) and take product 1 (2'-O-TBDMS). So the synthetic oligo uses 2' protection, which is standard in RNA synthesis (to prevent 2' OH from reacting during synthesis). After deprotection, it's natural.

But the question is: what is the relationship? If they deprotect, they are identical. So answer (B).

But wait, the problem says "naturally occurring RNA oligo with exactly the same types and sequence of bases". So if the synthetic one has the same sequence and bases, and after deprotection, it's identical to natural RNA, then answer is (B).

But why does the problem mention the COSY data? To confirm that product 1 is the 2'-O-TBDMS derivative (since the COSY correlations indicate Hb is coupled to H1' and H3', which would be the case for 2'-silylation).

Another angle: diastereomers. In RNA, the ribose is β-D-ribo, which has a specific stereochemistry. If the synthesis involved a different stereoisomer, it would be a diastereomer. But the starting material is β-D-ribonucleoside, so the stereochemistry is correct. Protecting the 2' OH with TBDMS doesn't change the stereochemistry (it's a substituent, not a chiral center), so no diastereomers.

So the answer should be (B) Identical.

Wait, but I'm not sure. Let's think again.

The problem states that the chemist is synthesizing an RNA nucleoside phosphoramidite from a β-D-ribonucleoside. The natural RNA uses β-D-ribose with 2' OH. The synthetic process protects the 2' OH with TBDMS (product 1), then makes the phosphoramidite. During solid-phase synthesis, the 2' TBDMS is used, and after synthesis, it's removed. So the final oligo is identical to natural RNA.

But the problem says "they compare their synthetic RNA oligo with a naturally occurring RNA oligo". If the synthetic one has been deprotected, they are identical. If not, they are not. But in standard practice, deprotection is done.

The problem might be designed to indicate that product 1 is the correct isomer (2' silylated) and not the 3' (which would lead to different stereochemistry), but since they use β-D-ribose, and the silylation is at 2' (which is not a chiral center), the stereochemistry remains the same.

Wait, the 2' carbon in ribose is a chiral center. In β-D-ribofuranose, the 2' OH is on the same side as the C3' OH (in the β configuration). Protecting it with TBDMS doesn't change the stereochemistry (it's just a substituent), so the synthetic oligo has the same stereochemistry as natural RNA.

Since the protecting groups are removed after synthesis, the final product is identical to natural RNA. So answer is (B).

But why the COSY data? To confirm that product 1 is 2'-O-TBDMS (not 3'-O-TBDMS), so they chose the correct isomer. If they had chosen product 2 (3'-O-TBDMS), the synthetic RNA would have different stereochemistry? No, because the 3' carbon is not a chiral center in the same way? Wait, in the furanose ring, C2' and C3' are chiral centers.

Wait, in ribose, C2' and C3' are chiral centers. In β-D-ribofuranose, the configuration is such that the OH groups are in specific positions. Protecting the 2' OH vs 3' OH would lead to different diastereomers because the sugar is chiral.

Ah! This is the key point I missed.

In the ribose sugar, C2' and C3' are chiral centers. When you protect the 2' OH vs 3' OH, you get diastereomers because the sugar is already chiral.

Wait, no: the starting material is a β-D-ribonucleoside, which has a specific stereochemistry at C2' and C3'. Protecting the 2' OH with TBDMS vs 3' OH would give two diastereomers because the sugar is chiral. But in reality, the 2' and 3' OH are diastereotopic protons.

Wait, in a chiral molecule, substituents at different chiral centers can lead to diastereomers.

But in this case, the ribonucleoside is already a single diastereomer (β-D-ribo). When you silylate either the 2' or 3' OH, you get two diastereomers (product 1 and product 2) because the 2' and 3' positions are diastereotopic.

So product 1 and product 2 are diastereomers.

The problem says they discard product 2 and take product 1. So they use the diastereomer where the TBDMS is on the 2' position.

Now, the question is: what is the relationship between the synthetic RNA oligo and natural RNA?

Natural RNA has the 2' OH. The synthetic oligo, after deprotection, has 2' OH. But during synthesis, they used the 2'-O-TBDMS protected nucleotides. After deprotection, they are identical.

But wait, if the synthetic process uses a diastereomer (product 1 is a diastereomer of the natural sugar), but the natural RNA is the β-D-ribo with 2' OH.

Wait, the starting material is β-D-ribonucleoside, which is the same as natural RNA. The silylation at 2' or 3' creates diastereomers because the sugar is chiral. But the natural RNA has the 2' OH, so the synthetic oligo after deprotection would have the same stereochemistry as natural RNA.

Wait, but if they silylated at 2', the diastereomer is still the same as natural RNA because the sugar's configuration is fixed. For example, in β-D-ribofuranose, the 2' OH is in a specific position (e.g., down or up), and silylation there doesn't change the stereochemistry.

Actually, the 2' and 3' OH groups are diastereotopic in the chiral sugar. Protecting one or the other gives diastereomers.

But in the problem, the chemist starts with a single β-D-ribonucleoside (so a specific diastereomer), and silylation at 2' or 3' gives two diastereomers (products 1 and 2).

They discard product 2 (the 3'-silylated diastereomer) and use product 1 (2'-silylated diastereomer). So the synthetic oligo has the same stereochemistry as the starting material (which is natural), because they chose the correct diastereomer (2'-silylated).

Thus, after deprotection, the synthetic RNA is identical to natural RNA.

But the problem states: "they compare their synthetic RNA oligo with a naturally occurring RNA oligo with exactly the same types and sequence of bases". So if the synthetic one has the same sequence and bases, and the same sugar stereochemistry, then they are identical.

The key point here is that the COSY data indicates that product 1 is the 2'-O-TBDMS derivative (not 3'), so they used the correct diastereomer. The natural RNA uses the 2' OH, so after deprotection, the synthetic RNA is identical.

Therefore, the answer is (B) Identical.

Wait, but I'm not sure. Another angle: in RNA synthesis, the 2' OH is protected to prevent it from reacting with the phosphoramidite. The synthetic process uses the 2'-O-TBDMS protected nucleotide, which is a standard approach. After synthesis, the 2' protecting groups are removed, yielding RNA with free 2' OH. So the final product is identical to natural RNA.

Yes, so answer is (B).

But why is the COSY data mentioned? To confirm that they used the 2'-O-TBDMS derivative (not 3'-O-TBDMS), which is the correct one for RNA synthesis (since 3'-O-TBDMS would lead to different properties, but in this case, they discarded product 2, so they used the correct one).

So the answer is (B).
</think>

The problem involves the synthesis of an RNA nucleoside phosphoramidite from a β-D-ribonucleoside, with a focus on the stereochemical and structural implications of the synthetic process compared to natural RNA.

---

### Key Steps in the Synthesis

1. **Initial Protection**: The 5'-OH of the β-D-ribonucleoside is protected with **DMTr** (dimethoxytrityl), a common protecting group for the 5' hydroxyl in RNA synthesis.
2. **Silylation**: The 5'-O-DMTr ribonucleoside is treated with **1.1 equivalents of TBDMSCl** (tert-butyldimethylsilyl chloride), which silylates the remaining hydroxyl groups (2' and 3').
   - This leads to **two products**: 
     - **Product 1**: 2'-O-TBDMS derivative
     - **Product 2**: 3'-O-TBDMS derivative
3. **Selection of Product 1**: The chemist discards product 2 and uses **product 1** (2'-O-TBDMS) for further synthesis.
4. **Phosphoramidite Formation**: Product 1 is converted into a nucleoside phosphoramidite using **2-cyanoethyl N,N-diisopropylchlorophosphoramidite**.
5. **Solid-Phase Synthesis**: The phosphoramidite is used to synthesize an RNA oligo via standard solid-phase methodology.

---

### NMR Analysis of Product 1

The 2D COSY NMR spectrum of **product 1** reveals:
- A correlation between a **1H doublet at ~6 ppm (Ha)** and a **1H doublet-of-doublets at ~4.5 ppm (Hb)**.
- A correlation between **Hb** and a **broad singlet at ~5.5 ppm**.
- A correlation between **Hb** and another **1H doublet-of-doublets at ~4.5 ppm (Hc)**.

This pattern is consistent with **H1' (anomeric proton)** coupling to **H2' (Hb)**, which in turn couples to **H3' (Hc)**. The **broad singlet at ~5.5 ppm** is likely due to a **free 3'-OH proton** (not silylated), indicating that **product 1 is the 2'-O-TBDMS derivative** (not 3'-O-TBDMS), as the 3'-OH is still present and exchanging.

This confirms that the chemist has selected the **correct diastereomer** (2'-O-TBDMS) for RNA synthesis, which is the standard configuration used in RNA synthesis.

---

### Comparison with Natural RNA

- **Natural RNA** consists of **β-D-ribofuranose** sugars with **free 2'-OH groups**.
- **Synthetic RNA** (after deprotection of the 2'-O-TBDMS group) has **identical base sequences** and **identical sugar stereochemistry** (β-D-ribofuranose) as natural RNA.
- The **TBDMS group** is **removed** during standard solid-phase RNA synthesis (as part of the deprotection step), yielding a **free 2'-OH** in the final oligo.

Thus, the **final synthetic RNA oligo** is **structurally and stereochemically identical** to **natural RNA** with the same base sequence.

---

### Why Not Other Options?

- **(A) Diastereoisomers**: Incorrect. The starting material is a single β-D-ribofuranose (a specific diastereomer), and the silylation at the 2' position does not alter the **stereochemistry** of the sugar (it's a substituent, not a chiral center). After deprotection, the synthetic RNA has the **same stereochemistry** as natural RNA.
- **(C) Constitutional isomers, but not regioisomers**: Incorrect. The difference between the synthetic and natural RNA is a **protecting group** (TBDMS) on the 2' position, not a change in connectivity. The **connectivity** of the sugar is the same (β-D-ribofuranose), so it is **not a constitutional isomer**.
- **(D) Regioisomers**: Incorrect. Regioisomers differ in the **position** of a functional group. Here, the functional group (TBDMS) is at the **same position** (2') in both the synthetic and natural RNA (after deprotection), so it is **not a regioisomer**.

---

### Final Conclusion

The synthetic RNA oligo, after deprotection of the 2'-O-TBDMS group, is **structurally and stereochemically identical** to natural RNA with the same base sequence.

Final answer: (B)
```

